Vistagen Therapeutics, Inc. 8-K

What Happened

• On May 8, 2026, Vistagen Therapeutics, Inc. announced via a press release (attached as Exhibit 99.1 to its Form 8‑K) that the last patient has completed their last visit in the randomized, double‑blind, placebo‑controlled portion of PALISADE‑4, the company’s Phase 3 trial of fasedienol nasal spray for the acute treatment of social anxiety disorder. The Form 8‑K was signed by President and CEO Shawn K. Singh.

Key Details

• Date filed: May 8, 2026 (Form 8‑K with Exhibit 99.1 press release).
• Trial: PALISADE‑4, Phase 3, randomized, double‑blind, placebo‑controlled portion completed.
• Drug/Indication: fasedienol nasal spray for acute treatment of social anxiety disorder.
• Milestone: last patient completed last visit in the randomized/placebo‑controlled portion.

Why It Matters

• Completion of the randomized, double‑blind, placebo‑controlled portion of a Phase 3 study is a key clinical milestone. It typically precedes data clean‑up, analysis and any subsequent announcements about topline results or next steps in development. Investors should watch for future company updates reporting analysis results, timing for database lock, or regulatory plans.